research use only

RMC-6291 Ras inhibitor

Cat.No.E1606

RMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON). This compound forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA).
RMC-6291 Ras inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 1012.26

Quality Control

Batch: E160601 DMSO]100 mg/mL]false]Ethanol]100 mg/mL]false]Water]Insoluble]false Purity: 99.03%
99.03

Chemical Information, Storage & Stability

Molecular Weight 1012.26 Formula

C55H78FN9O8

Storage (From the date of receipt)
CAS No. 2641998-63-0 Download SDF Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (98.78 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
KRAS-G12C(ON) [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06128551 Recruiting
Non-Small Cell Lung Cancer (NSCLC)|Colorectal Cancer|Pancreatic Ductal Adenocarcinoma
Revolution Medicines Inc.
November 14 2023 Phase 1
NCT05462717 Recruiting
Non-Small Cell Lung Cancer (NSCLC)|Colorectal Cancer (CRC)|Pancreatic Ductal Adenocarcinoma|Advanced Solid Tumor
Revolution Medicines Inc.
September 19 2022 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map